In partnership with
Privacy-first email. Built for real protection.
Proton Mail offers what others won’t:
End-to-end encryption by default
Zero access to your data
Open-source and independently audited
Based in Switzerland with strong privacy laws
Free to start, no ads
We don’t scan your emails. We don’t sell your data. And we don’t make you dig through settings to find basic security. Proton is built for people who want control, not compromise.
Simple, secure, and free.
AGENTIC AI
1. The AI case manager for every prescription in America just tripled its valuation in four months.
The signal: Forus raised $150M in Series C at a $3B valuation, led by Bain Capital Ventures, with every existing institutional investor returning. The platform gives each prescription its own AI agent that navigates insurance, prior authorization, financial assistance, and pharmacy logistics, free for providers and patients.
The details:
One in three patients prescribed high-cost or complex therapies never receives their first dose. Forus CEO Sahir Jaggi built the platform to close that gap: AI agents work inside provider workflows and handle all case management after the clinical decision is made. Family Allergy & Asthma reports prior authorization turnaround went from 7+ days to a median 1.1 days. DOCS Dermatology says 80% more patients got their medication.
Now used by providers across all 50 states, covering 85% of U.S. residential ZIP codes. More than a third of providers nationally have adopted Forus in its first specialty. It works with 9 of the top 15 global biopharma companies. The Series C, just four months after a Series B that valued the company at $1B, brings total funding past $300M.
Investors include Thrive Capital, General Catalyst, Accel, Redpoint, and SV Angel. Every existing institutional investor returned for this round, per Bain Capital Ventures general partner Kevin Zhang.
Why it matters: This is what it looks like when the access layer gets properly funded. The algorithm was never the bottleneck, the tangle of payer portals, fax lines, and patient financial situations was. A $3B valuation for a company that still charges providers nothing to use means the biopharma and data economics are large enough to carry the whole thing. That changes the investment case for the entire prescription-access category.
PHARMA & AI
2. An AI designed this drug from scratch. Yesterday it showed six independent aging clocks all pointing younger.
The signal: Insilico Medicine's rentosertib, an AI-discovered-and-designed drug for idiopathic pulmonary fibrosis (a fatal lung scarring disease with a median survival of 3-4 years), published secondary Phase IIa data in Nature Biotechnology showing that six independently built proteomic aging clocks all detected measurable biological age reversal in treated patients. CEO Alex Zhavoronkov presented the results at the Nature 'Redefining Healthcare in the Age of AI' conference at Sorbonne University in Paris on September 8.
The details:
42 IPF patients had blood samples tracked over 12 weeks. Six aging clocks, developed separately by teams at Harvard Medical School, Oxford, Peking University, and Insilico, all showed reduced predicted biological age in treated groups versus placebo. Effect averaged 3-4 years of reversal on most clocks, up to 6 years on one. These clocks share neither features nor training data.
Rentosertib is the first drug candidate where both the target and the molecule were discovered and designed by AI: Insilico's PandaOmics platform identified the TNIK target, and Chemistry42 generated the molecule. Target to clinical candidate took 18 months. The drug entered Phase III in China on July 7, 2026. Phase III targets 320 patients over 52 weeks, measuring lung function.
Key caveat from the authors: this trial cannot yet separate genuine aging slowdown from the effect of treating a diseased lung. Nobel laureate Michael Levitt said the inter-clock agreement convinces him the effect is real, but named a healthy-volunteer trial as the next required experiment. framework prioritizes continuous remote sensor data to replace intermittent site visits with automated endpoint verification.
Why it matters: This is the first published clinical evidence that an entirely AI-designed drug candidate can move aging biomarkers in a prospective trial. The science is uncertain but the framework it establishes (embedding aging clocks as secondary endpoints inside disease trials) is the part that matters for the industry. Every pharma team running a longevity program just got a published methodology template.
EHR PLATFORMS
3. Adventist Health just put 27 hospitals on one record. Oracle Health lost another major system.
Caption: Source: Adventist Health newsroom, adventisthealth.org
The signal: Adventist Health completed its $500M go-live on Epic, uniting 27 hospitals and more than 440 clinics in California, Oregon, and Hawaii under a single connected health record. The health system had announced its move away from Oracle Health in August 2024. As of today, the migration is live system-wide.
The details:
Adventist Health processes about 5 million patient encounters and 3 million clinic visits per year. Previously, patient information was spread across separate systems. The Epic go-live means care teams anywhere in the network see the full patient record in one place. Patients get a single MyChart account for the entire system. CIO Jennifer Stemmler led the integration; CEO Kerry Heinrich described it as a mission decision, not just an IT project.
The $500M investment was funded partly through $1B in tax-exempt bonds from California's Health Facilities Financing Authority. It replaces multiple legacy EMRs, including Cerner (now Oracle Health). At Adventist's scale (28 hospitals, hundreds of clinics), this is the definition of a whole-platform bet.
Context: Oracle Health's market share at large U.S. health systems has fallen to approximately 27% versus Epic's 48%. Vandalia Health (reported September 1) is also switching from Oracle to Epic. 14 federal agencies expressed interest today in joining the Federal EHR Modernization program, which runs Oracle Health at the VA. The VA has 14 of 164 hospitals live after six years. are heavily favoring companies building full clinical operating layers over narrow, single-feature AI wrappers.
Why it matters: When a 27-hospital system bets $500M on a platform switch, it is a market statement, not just an IT project. Oracle Health's decline from Cerner is accelerating: the VA, Vandalia, and now Adventist are three very different data points pointing the same way. The EHR market is consolidating around Epic faster than most predicted three years ago.